Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,198 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials.
Metra M, Eichhorn E, Abraham WT, Linseman J, Böhm M, Corbalan R, DeMets D, De Marco T, Elkayam U, Gerber M, Komajda M, Liu P, Mareev V, Perrone SV, Poole-Wilson P, Roecker E, Stewart J, Swedberg K, Tendera M, Wiens B, Bristow MR; ESSENTIAL Investigators. Metra M, et al. Among authors: gerber m. Eur Heart J. 2009 Dec;30(24):3015-26. doi: 10.1093/eurheartj/ehp338. Eur Heart J. 2009. PMID: 19700774 Free PMC article. Clinical Trial.
Rationale and design of the enoximone clinical trials program.
Lowes BD, Shakar SF, Metra M, Feldman AM, Eichhorn E, Freytag JW, Gerber MJ, Liard JF, Hartman C, Gorczynski R, Evans G, Linseman JV, Stewart J, Robertson AD, Roecker EB, Demets DL, Bristow MR. Lowes BD, et al. Among authors: gerber mj. J Card Fail. 2005 Dec;11(9):659-69. doi: 10.1016/j.cardfail.2005.10.013. J Card Fail. 2005. PMID: 16360960
Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial.
Feldman AM, Oren RM, Abraham WT, Boehmer JP, Carson PE, Eichhorn E, Gilbert EM, Kao A, Leier CV, Lowes BD, Mathier MA, McGrew FA, Metra M, Zisman LS, Shakar SF, Krueger SK, Robertson AD, White BG, Gerber MJ, Wold GE, Bristow MR; EMOTE Study Group. Feldman AM, et al. Among authors: gerber mj. Am Heart J. 2007 Nov;154(5):861-9. doi: 10.1016/j.ahj.2007.06.044. Epub 2007 Sep 6. Am Heart J. 2007. PMID: 17967591 Clinical Trial.
Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.
Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ; Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Galiè N, et al. Circulation. 2008 Jun 10;117(23):3010-9. doi: 10.1161/CIRCULATIONAHA.107.742510. Epub 2008 May 27. Circulation. 2008. PMID: 18506008 Clinical Trial.
Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study.
Black HR, Bakris GL, Weber MA, Weiss R, Shahawy ME, Marple R, Tannoury G, Linas S, Wiens BL, Linseman JV, Roden R, Gerber MJ. Black HR, et al. J Clin Hypertens (Greenwich). 2007 Oct;9(10):760-9. doi: 10.1111/j.1524-6175.2007.07244.x. J Clin Hypertens (Greenwich). 2007. PMID: 17917503 Free PMC article. Clinical Trial.
New Generation Self-Replicating RNA Vaccines Derived from Pestivirus Genome.
Démoulins T, Techakriengkrai N, Ebensen T, Schulze K, Liniger M, Gerber M, Nedumpun T, McCullough KC, Guzmán CA, Suradhat S, Ruggli N. Démoulins T, et al. Among authors: gerber m. Methods Mol Biol. 2024;2786:89-133. doi: 10.1007/978-1-0716-3770-8_4. Methods Mol Biol. 2024. PMID: 38814391
Cardiorespiratory fitness, perceived fitness and autonomic function in in-patients with different depression severity compared with healthy controls.
Kreppke JN, Cody R, Beck J, Brand S, Donath L, Eckert A, Imboden C, Hatzinger M, Holsboer-Trachsler E, Lang UE, Mans S, Mikoteit T, Oswald A, Rogausch A, Schweinfurth-Keck N, Zahner L, Gerber M, Faude O. Kreppke JN, et al. Among authors: gerber m. J Psychiatr Res. 2024 May 21;175:437-445. doi: 10.1016/j.jpsychires.2024.05.044. Online ahead of print. J Psychiatr Res. 2024. PMID: 38797040 Free article.
1,198 results